Co-Diagnostics, Inc. (CODX) Stock Price & Analysis
Co-Diagnostics, Inc. (CODX) — MoonshotScore 18/100 (Weak band), calculated Nov 18, 2026. Price $0.1295 (-21.32%), as of the Nov 20, 2026 trading session; market cap $1.36M.
Educational signal · not a buy or sell recommendation · How to read this
Co-Diagnostics, Inc. · CODX · NASDAQ
Co-Diagnostics, Inc. is a molecular diagnostics company specializing in PCR-based testing solutions. The company develops, manufactures, and sells diagnostic reagents for various infectious diseases and genetic conditions.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Co-Diagnostics (CODX)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet and stalling growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Falling.
- quarterly revenue $145,380 (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 3 reports
- Altman Z -23.19 · Piotroski F 2
Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak | |
| 18 | Weak | |
| 18 | Weak | |
| 18 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.1295 | |
| Change on the day | -21.32% | |
| Market capitalisation | $1.36M | — |
| Price / earnings (trailing) | -0.12 | |
| Shares traded on the day | 1.14M |
Price & events
Other perspectives
Council score for Co-Diagnostics (CODX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Co-Diagnostics (CODX), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Co-Diagnostics, Inc. (CODX) is listed on NASDAQ. It employs 115 people. In Q3 FY2025 it reported revenue of $145,380 and net income of -$6M. The market values it at $1.36M.
What do the latest results show for Co-Diagnostics (CODX)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $145,380. Against analyst estimates the company has EPS beat 0 of the last 3 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $145,380 | -$6M | -$4.66 (diluted) |
| Q4 FY2025 | $263,922 | -$26M | — |
| Q1 FY2026 | $145,954 | -$9M | -$4.06 (diluted) |
| Q2 FY2026 | $166,131 | -$6M | -$1.46 (diluted) |
What are the financial strengths and risks for Co-Diagnostics (CODX)?
Short answer · as of
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -23.19 · Piotroski F 2. Trailing ratios: ROA -63.7% · current ratio 0.77.
Data-derived red flags
- Listing risk — at $0.1295 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -23.19 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How does Co-Diagnostics compare with its peers?
Short answer
Co-Diagnostics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $8.52 Nov 20, 2026 | $323M | 88 5-pillar Nov 18, 2026 | |
| $22.98 Nov 20, 2026 | $188M | 87 5-pillar Nov 18, 2026 | |
| $8.73 Nov 19, 2026 | $351M | 87 5-pillar Nov 18, 2026 | |
| $13.23 Nov 20, 2026 | $177M | 71 5-pillar Nov 18, 2026 | |
| $4.64 Nov 19, 2026 | $57.1M | 44 5-pillar Nov 18, 2026 | |
| $1.49 Nov 20, 2026 | $93.7M | 43 5-pillar Nov 18, 2026 | |
| $3.23 Nov 19, 2026 | $96.5M | 41 5-pillar Nov 18, 2026 | |
| $2.08 Nov 20, 2026 | $31.7M | 39 5-pillar Nov 18, 2026 | |
| $5.30 Nov 20, 2026 | $138M | 37 5-pillar Nov 18, 2026 | |
| $6.07 Nov 20, 2026 | $247M | 36 5-pillar Nov 18, 2026 | |
| $2.39 Nov 19, 2026 | $101M | 33 5-pillar Nov 18, 2026 | |
| $1.27 Nov 20, 2026 | $255M | 32 5-pillar Nov 18, 2026 | |
| Co-Diagnostics (CODX) — this page | $0.1295 | $1.36M | 18 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 5
- Purchases
- 0
- Sales
- 0
- Other transactions
- 12
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CODX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CODX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Co-Diagnostics (CODX)?
Investor Questions: CODX Stock
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for CODX?
CODX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Co-Diagnostics, Inc. is a molecular diagnostics company specializing in PCR-based testing solutions.
Is CODX a good stock to buy?
Stock Expert AI does not rate CODX buy, sell or hold. Co-Diagnostics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CODX stock price today?
The last price recorded for Co-Diagnostics, Inc. (CODX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for CODX?
Co-Diagnostics, Inc. (CODX) holds a MoonshotScore in the low range. Co-Diagnostics operates in the molecular diagnostics market, which is projected to grow due to increasing demand for rapid and accurate testing. Not financial advice.
How frequently does CODX data refresh on this page?
CODX's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CODX's recent stock price performance?
Co-Diagnostics, Inc. (CODX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Co-Dx PCR platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CODX overvalued or undervalued right now?
Co-Diagnostics, Inc. (CODX) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CODX?
Fractional-share availability for Co-Diagnostics, Inc. (CODX) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
How can I track CODX's earnings and financial reports?
Co-Diagnostics, Inc. (CODX) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for CODX earnings announcements.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 12 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com